The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.
Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.
| Metrics | Current | 2025 | 2024 | 2023 |
|---|---|---|---|---|
|
Value
|
3 | 1 | 1 | 1 |
|
Growth
|
83 | 82 | 100 | 93 |
|
|
36 | 4 | 6 | 22 |
|
Sentiment
|
31 | 88 | 59 | 52 |
|
|
8 | 35 | 27 | 25 |
| Metrics | Current | 2025 | 2024 | 2023 |
|---|---|---|---|---|
|
Analyst Opinions
|
48 | 60 | 63 | 59 |
|
Opinions Change
|
37 | 50 | 55 | 50 |
|
Pro Holdings
|
n/a | 78 | 30 | 22 |
|
Market Pulse
|
41 | 82 | 84 | 70 |
|
Sentiment
|
31 | 88 | 59 | 52 |
| Metrics | Current | 2025 | 2024 | 2023 |
|---|---|---|---|---|
|
Value
|
3 | 1 | 1 | 1 |
|
Growth
|
83 | 82 | 100 | 93 |
|
Safety
|
36 | 4 | 6 | 22 |
|
Combined
|
23 | 7 | 16 | 30 |
| Metrics | Current | 2025 | 2024 | 2023 |
|---|---|---|---|---|
|
Price vs. Sales (P/S)
|
13 | 5 | 1 | 3 |
|
Price vs. Earnings (P/E)
|
16 | 7 | 1 | 1 |
|
Price vs. Book (P/B)
|
3 | 1 | 1 | 3 |
|
Dividend Yield
|
1 | 1 | 1 | 1 |
|
Value
|
3 | 1 | 1 | 1 |
| Metrics | Current | 2025 | 2024 | 2023 |
|---|---|---|---|---|
|
Revenue Growth
|
93 | 98 | 98 | 81 |
|
Profit Growth
|
30 | 6 | 81 | 88 |
|
Capital Growth
|
100 | 60 | 73 | 91 |
|
Stock Returns
|
47 | 88 | 85 | 9 |
|
Growth
|
83 | 82 | 100 | 93 |
| Metrics | Current | 2025 | 2024 | 2023 |
|---|---|---|---|---|
|
Leverage
|
47 | 19 | 19 | 70 |
|
Refinancing
|
25 | 6 | 15 | 11 |
|
Liquidity
|
59 | 10 | 6 | 1 |
|
Safety
|
36 | 4 | 6 | 22 |
Discover high‑ranked alternatives to SK Biopharmaceuticals and broaden your portfolio horizons.
South Korea
South Korea
Hong Kong
This is a classic, high-risk growth play: high growth and positive sentiment outweigh low Value Rank (expensive) and risky financing. This is for aggressive growth investors who are comfortable with the high price and risk, believing the growth story justifies the expense.
Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.
The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.
Become an Obermatt subscriber and see all of the similar stocks here.
The Obermatt Advantage
Choose the Obermatt subscription that best fits your needs.
Top 10
Market ListsSimilar
Stocks1
WatchlistDelivered to your inboxTop 10
Market ListsSimilar
Stocks
Stock
Filters6 key
ranks for 6,500+ stocks3
WatchlistsDelivered to your inboxTop 10
Market ListsSimilar
StocksStock
FiltersInvestment
Themes6 key
ranks for 6,500+ stocks15 more
detailed ranks3 years of
historical ranksUnlimited
WatchlistsDelivered to your inbox
30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at
any time.
See how Obermatt improved their investing:
Add to Watchlist
See Similar Stocks
Japan